Analysts’ Recent Ratings Changes for Belite Bio (BLTE)

Belite Bio (NASDAQ: BLTE) has recently received a number of price target changes and ratings updates:

• 9/9/2026 – Belite Bio had its price target raised by Mizuho from $220.00 to $234.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Belite Bio had its “hold” rating reaffirmed by Jefferies Financial Group Inc..
• 9/8/2026 – Belite Bio was given a new $245.00 price target by HC Wainwright.
• 9/4/2026 – Belite Bio is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $303.00 price target on the stock.
• 9/4/2026 – Belite Bio is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $303.00 price target on the stock.
• 9/3/2026 – Belite Bio had its “buy” rating reaffirmed by UBS Group AG.
• 9/3/2026 – Belite Bio had its price target raised by HC Wainwright from $214.00 to $245.00. They now have a “buy” rating on the stock.
• 8/18/2026 – Belite Bio was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/14/2026 – Belite Bio had its price target raised by Morgan Stanley from $201.00 to $206.00. They now have an “overweight” rating on the stock.
• 8/14/2026 – Belite Bio had its “buy” rating reaffirmed by Benchmark Co..
• 8/14/2026 – Belite Bio was given a new $220.00 price target by Mizuho.
• 8/12/2026 – Belite Bio had its price target raised by Cantor Fitzgerald from $266.00 to $270.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Belite Bio had its price target raised by HC Wainwright from $200.00 to $214.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other news, CEO Yu-Hsin Lin sold 26,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $196.56, for a total value of $5,110,560.00. Following the completion of the sale, the chief executive officer owned 70,134 shares of the company’s stock, valued at $13,785,539.04. This represents a 27.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Hao-Yuan Chuang sold 17,962 shares of Belite Bio stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $196.42, for a total transaction of $3,528,096.04. Following the sale, the chief financial officer directly owned 26,038 shares in the company, valued at $5,114,383.96. This trade represents a 40.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 168,562 shares of company stock valued at $32,018,474. Insiders own 13.29% of the company’s stock.

Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious retinal diseases. The company’s research centers on therapies designed to address the underlying biological processes that contribute to vision loss, including the accumulation of toxic vitamin A–derived compounds in the retina.

Belite Bio’s lead product candidate is tinlarebant, also known as LBS-008. Tinlarebant is an orally administered retinol-binding protein 4 antagonist intended to reduce the delivery of vitamin A to the retina and limit the formation of toxic bisretinoids.